

# Validation of a rabbit model of *in vivo* biofilm formation on beads for *ex vivo* evaluation of the antibiofilm activity of antistaphylococcal drugs

P1014

L. Coignet<sup>1,2</sup>, S. Jamard<sup>1,3</sup>, A. Passaret<sup>2,4</sup>, C. Vogt<sup>2,4</sup>, T. Mezieres<sup>2,4</sup>, J. Josse<sup>2,1</sup>, T. Ferry<sup>2,1,5</sup>, F. Laurent<sup>2,6,1</sup>, F. Valour<sup>2,1,5</sup>


<sup>1</sup>Centre International de Recherche en Infectiologie, Inserm U1111, UMR5308, <sup>2</sup>Université Claude Bernard Lyon 1, <sup>3</sup>Service des maladies infectieuses, CHRU de Tours, - Tours (France), <sup>4</sup>Ecole de chirurgie de Lyon, UCBL1, <sup>5</sup>Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, CRIOAc Lyon, Hospices Civils de Lyon, <sup>6</sup>Institut des agents infectieux, Laboratoire de bactériologie, CNR des staphylocoques, CRIOAc Lyon, Hospices Civils de Lyon - Lyon (France)

## Rational

- Determination of antibiofilm activity of antimicrobials is a prerequisite for treatment of device-associated infections.
- Current *in vitro* models shows important variations upon technical conditions.
- On the other hand, animal models only allow the evaluation of a limited number of conditions.


## Description of the model

- Implantation of 6 cylindrical (30x10mm) cages *per* rabbit containing 6 beads (Ø 5mm) of polyethylene (UHMWPE), titanium or stainless steel
- Infection at D14 by a standardized inoculum of *S. aureus* SH1000
- Cage harvesting after biofilm formation to use beads for bacterial quantification, biofilm imaging and MBEC determination



## *In vitro* biofilm formation on beads

- Incubation of cages for 24h in a standardized bacterial solution in RPMI, TSB and TSB + 1% glucose
- Lavage and sonication of each bead for bacterial quantification




- Confirmation of a significant impact of culture condition on biofilm formation, justifying *in vivo/ex vivo* evaluations
- No difference between biomaterials, allowing choosing UHMWPE for animal experiments, due to its lighter weight

## Objectives

Description of a rabbit tissue-cage model allowing *ex vivo* screening of a large panel of molecules against *in vivo*-formed biofilm with a limited number of animals

## Characterization of the *in vivo* model of biofilm formation on UHMWPE beads

- Evaluation of increasing inocula (500/1000/2000 UFC/cage) and harvesting times (7/14/28 days post-infection)




- Number of sterile cages increased significantly with time : 6.7%, 20.0% and 33.3% at day 7, 14 and 28, respectively
- Histopathological analysis of cage-surrounding membranes showing chronic inflammation (collagenous fibrosis, fibrin and granulation tissue)

→ Choice of the minimum infecting inoculum of 500 CFU/cage for 14 days of infection for further experiments, including MBEC determination, due to its best reproducibility/chronicity ratio

## Vancomycin, daptomycin and rifampin MBEC determined by the reference *in vitro* MBEC assay, and on UHMWPE bead-associated *in vitro* and *in vivo* formed biofilm

	<i>in vitro</i> MBEC assay®	UHMWPE bead-associated biofilm	
		<i>In vitro</i> (p-value for MBEC assay® comparison)	<i>Ex vivo</i> (p-value for <i>in vitro</i> -formed bead-associated biofilm comparison)
Vancomycin (mg/L)	4.50	13.3 (p=0.07)	1 (p=0.04)
Daptomycin (mg/L)	3.25	4 (p=0.88)	1.5 (p=0.027)
Rifampin (mg/L)	0.062	0.333 (p=0.05)	<0.016 (p=0.04)



→ MBEC90 determined on bead-associated biofilms were significantly lower on *in vivo* formed biofilm compared to *in vitro*.

This new rabbit model allows *ex vivo* evaluation of the antibiofilm activity of antistaphylococcal drugs on *in vivo*-formed biofilm with a limited number of animals, showing significant variations compared to the reference method for MBEC determination.